Arcus Biosciences Inc (RCUS) — Cash Flow-to-Debt Ratio
Arcus Biosciences Inc (RCUS) has a Cash Flow-to-Debt Ratio of -0.29x as of March 2026, meaning its operating cash flow of $-138.00 Million could theoretically repay 0% of its total liabilities ($473.00 Million) in one year. See free cash flow generation of Arcus Biosciences Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arcus Biosciences Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Arcus Biosciences Inc across 10 annual periods. Also explore net asset momentum of Arcus Biosciences Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Arcus Biosciences Inc (2016–2025)
Year-by-year debt coverage analysis for Arcus Biosciences Inc. For market capitalisation and broader financial context, see Arcus Biosciences Inc (RCUS) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.95x | $-482.00 Million | $508.00 Million | ▼ -271.2% |
| 2024 | -0.26x | $-170.00 Million | $665.00 Million | ▲ +47.1% |
| 2023 | -0.48x | $-306.00 Million | $633.00 Million | ▼ -175.9% |
| 2022 | 0.64x | $438.00 Million | $688.00 Million | ▲ +286.5% |
| 2021 | -0.34x | $-256.17 Million | $750.45 Million | ▼ -182.9% |
| 2020 | 0.41x | $111.17 Million | $269.99 Million | ▲ +122.0% |
| 2019 | -1.87x | $-73.46 Million | $39.27 Million | ▼ -74.0% |
| 2018 | -1.08x | $-43.00 Million | $39.98 Million | ▼ -57.1% |
| 2017 | -0.68x | $-25.06 Million | $36.62 Million | ▲ +45.9% |
| 2016 | -1.26x | $-12.94 Million | $10.24 Million | — |